Inhibition of atherosclerosis in apolipoprotein-E-deficient mice following muscle transduction with adeno-associated virus vectors encoding human apolipoprotein-E

被引:0
作者
JD Harris
S Schepelmann
T Athanasopoulos
IR Graham
AK Stannard
Z Mohri
V Hill
DG Hassall
JS Owen
G Dickson
机构
[1] Centre for Biomedical Research,Department of Medicine
[2] School of Biological Sciences,undefined
[3] Royal Holloway,undefined
[4] University of London,undefined
[5] Centre of Hepatology,undefined
[6] Royal Free and University College Medical School,undefined
[7] GlaxoSmithKline,undefined
[8] Medicines Research Centre,undefined
来源
Gene Therapy | 2002年 / 9卷
关键词
gene therapy; apolipoprotein E; atherosclerosis; AAV;
D O I
暂无
中图分类号
学科分类号
摘要
Apolipoprotein E (apoE) is a multifunctional plasma glycoprotein involved in lipoprotein metabolism and a range of cell signalling phenomena. ApoE-deficient (apoE-/-) mice exhibit severe hypercholesterolaemia and are an excellent model of human atherosclerosis. ApoE somatic gene transfer and bone marrow transplantation in apoE-/- mice results in reversal of hypercholesterolaemia, inhibition of atherogenesis and regression of atherosclerotic plaque density. Replication defective adeno-associated virus vectors (rAAVs) are an attractive system currently in clinical trial for muscle-based heterologous gene therapy to express secreted recombinant plasma proteins. Here we have applied rAAV transduction of skeletal muscle to express wild-type (ɛ3) and a defective receptor-binding mutant (ɛ2) human apoE transgene in apoE-/- mice. In treated animals, apoE mRNA was present in transduced muscles and, although plasma levels of recombinant apoE fell below the detection levels of our ELISA (ie <10 ng/ml), circulating antibodies to human apoE and rAAV were induced. Up to 3 months after a single administration of rAAV/apoE3, a significant reduction in atherosclerotic plaque density in aortas of treated animals was observed (approximately 30%), indicating that low-level rAAV-mediated apoE3 expression from skeletal muscle can retard atherosclerotic progression in this well-defined genetic model.
引用
收藏
页码:21 / 29
页数:8
相关论文
共 107 条
  • [41] Linden RM(1999)Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX-mediated by adeno-associated viral vector Nat Med 56 56-undefined
  • [42] Samulski RJ(1998)Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers J Virol 72 4212-undefined
  • [43] Chang LS(2000)Low levels of extrahepatic nonmacrophage apoE inhibit atherosclerosis without correcting hypercholesterolemia in ApoE-deficient mice Arterioscler Thromb Vasc Biol 20 1939-undefined
  • [44] Shenk T(1999)Ultrastructure of early lipid accumulation in apoE deficient mice Arterioscler Thromb Vasc Biol 19 847-undefined
  • [45] Kessler PD(1997)Apolipoprotein E Inhibits platelet aggregation through the L-arginine:nitric oxide pathway J Biol Chem 272 89-undefined
  • [46] Blau HM(1994)Apolipoprotein E inhibition of proliferation of mitogen-activated T lymphocytes: production of interleukin 2 with reduced biological activity Cell Immunol 159 124-undefined
  • [47] Springer M(1998)Apolipoprotein E inhibits platelet-derived growth factor-induced vascular smooth muscle cell migration and proliferation by suppressing signal transduction and preventing cell entry to G1 phase J Biol Chem 273 20156-undefined
  • [48] Xiao X(1998)Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the apoE-deficient mouse Arterioscler Thromb Vasc Biol 18 842-undefined
  • [49] Li J(1998)Antioxidants and coronary artery disease Curr Opin Lipidol 9 541-undefined
  • [50] Samulski RJ(1999)Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries, and paradoxes J Lipid Res 40 1933-undefined